AAAAAA

   
Results: 1-8 |
Results: 8
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients withosteoarthritis
Authors: Truitt, KE Sperling, RS Ettinger, WH Greenwald, M DeTora, L Zeng, Q Bolognese, J Ehrich, E
Citation: Ke. Truitt et al., A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients withosteoarthritis, AGING-CLIN, 13(2), 2001, pp. 112-121
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors
Authors: Detora, LM Krupa, D Bolognese, J Sperling, RS Ehrich, EW
Citation: Lm. Detora et al., Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors, J RHEUMATOL, 28(11), 2001, pp. 2494-2503
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
Authors: Konstam, MA Weir, MR Reicin, A Shapiro, D Sperling, RS Barr, E Gertz, BJ
Citation: Ma. Konstam et al., Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib, CIRCULATION, 104(19), 2001, pp. 2280-2288
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatalexposure to zidovudine
Authors: Hanson, IC Antonelli, TA Sperling, RS Oleske, JM Cooper, E Culnane, M Fowler, MG Kalish, LA Lee, SS McSherry, G Mofenson, L Shapiro, DE
Citation: Ic. Hanson et al., Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatalexposure to zidovudine, J ACQ IMM D, 20(5), 1999, pp. 463-467
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements
Authors: Brambilla, D Reichelderfer, PS Bremer, JW Shapiro, DE Hershow, RC Katzenstein, DA Hammer, SM Jackson, B Collier, AC Sperling, RS Fowler, MG Coombs, RW
Citation: D. Brambilla et al., The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements, AIDS, 13(16), 1999, pp. 2269-2279
Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load
Authors: Shapiro, DE Coombs, RW Sperling, RS
Citation: De. Shapiro et al., Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load, LANCET, 354(9173), 1999, pp. 156-156
Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis
Authors: Shapiro, DE Sperling, RS Mandelbrot, L Britto, P Cunningham, BE
Citation: De. Shapiro et al., Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis, OBSTET GYN, 94(6), 1999, pp. 897-908
The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076)
Authors: McSherry, GD Shapiro, DE Coombs, RW McGrath, N Frenkel, LM Britto, P Culnane, M Sperling, RS
Citation: Gd. Mcsherry et al., The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076), J PEDIAT, 134(6), 1999, pp. 717-724
Risultati: 1-8 |